K. Maurizi, G. Motte, J.-P. Durande, V. Roth, J-M Ferrero, J. Rottembourg, Antoine Thyss, Henri Boulanger, O. Moranne, M. Ducret, Gilbert Deray, Vincent Launay-Vacher, Z. Soltani, M. S. Islam, Nicolas Janus, Juliette Thariat, and L. Juillard
e13562 Background: 1 million people worldwide benefit from chronic dialysis with an increased rate in Western countries of 5% yearly. Significant improvements of chronic renal replacement therapy have led to prolonged survival. Due to mean age and heightened incidence of many cancers in dialyzed pts, the management of pts who suffer from both cancer and end-stage renal disease is challenging for oncologists and nephrologists. Specific questions were addressed to assess the efficacy/toxicity ratio, namely life expectancy, toxicity/dialysis clearance/optimal timing of chemotherapy. Methods: Retrospective multicentre review of dialysis centre charts for pts under dialysis who subsequently had a cancer. Results: Among 178 patients (66% male, median age 69) from 12 institutions, 35% were GU, 23% GI, lung 14%, hematologic 10%, head and neck 8%, or various others 10%. Most common histologies were adenocarcinomas 47%, of hematologic origin 17% and urothelial carcinomas 12%. Physical status was 0 48%, 1 18%, 2 30%...